Literature DB >> 25917047

A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.

Masataka Nakamura1, Kevin F Bieniek, Wen-Lang Lin, Neill R Graff-Radford, Melissa E Murray, Monica Castanedes-Casey, Pamela Desaro, Matthew C Baker, Nicola J Rutherford, Janice Robertson, Rosa Rademakers, Dennis W Dickson, Kevin B Boylan.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a degenerative disorder affecting upper and lower motor neurons, but it is increasingly recognized to affect other systems, with cognitive impairment resembling frontotemporal dementia (FTD) in some patients. We report clinical and pathologic findings of a family with ALS due to a truncating mutation, p.Gly141X, in copper/zinc superoxide dismutase (SOD1). The proband presented clinically with FTD and later showed progressive motor neuron disease, while all other family members had early-onset and rapidly progressive ALS without significant cognitive deficits. Pathologic examination of both the proband and her daughter revealed degeneration of corticospinal tracts and motor neurons in brain and spinal cord compatible with ALS. On the other hand, the proband also had neocortical and limbic system degeneration with pleomorphic neuronal cytoplasmic inclusions. Extramotor pathology in her daughter was relatively restricted to the hypothalamus and extrapyramidal system, but not the neocortex. The inclusions in the proband and her daughter were immunoreactive for SOD1, but negative for TAR DNA-binding protein of 43 kDa (TDP-43). In the proband, a number of the neocortical inclusions were immunopositive for α-internexin, initially suggesting a diagnosis of atypical FTLD, but there was no evidence of fused in sarcoma (FUS) immunoreactivity, which is often detected in atypical FTLD. Analogous to atypical FTLD, neuronal inclusions had variable co-localization of SOD1 and α-internexin. The current classification of FTLD is based on the major constituent protein: FTLD-tau, FTLD-TDP-43, and FTLD-FUS. The proband in this family indicates that SOD1, while rare, can also be the substrate of FTLD, in addition to the more common presentation of ALS. The explanation for clinical and pathologic heterogeneity of SOD1 mutations, including the p.Gly141X mutation, remains unresolved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917047      PMCID: PMC5039014          DOI: 10.1007/s00401-015-1431-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  37 in total

1.  Accumulation of neurofilaments and SOD1-immunoreactive products in a patient with familial amyotrophic lateral sclerosis with I113T SOD1 mutation.

Authors:  Y Kokubo; S Kuzuhara; Y Narita; K Kikugawa; R Nakano; T Inuzuka; S Tsuji; M Watanabe; T Miyazaki; S Murayama; Y Ihara
Journal:  Arch Neurol       Date:  1999-12

2.  Combined fulminant frontotemporal dementia and amyotrophic lateral sclerosis associated with an I113T SOD1 mutation.

Authors:  Jonathan S Katz; Hans D Katzberg; Susan C Woolley; Stefan L Marklund; Peter M Andersen
Journal:  Amyotroph Lateral Scler       Date:  2012-06-07

Review 3.  Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features.

Authors:  A Radunovíc; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

4.  Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS).

Authors:  Susan C Woolley; Michele K York; Dan H Moore; Adriana M Strutt; Jennifer Murphy; Paul E Schulz; Jonathan S Katz
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

5.  The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships.

Authors:  Julie S Snowden; Jennifer C Thompson; Cheryl L Stopford; Anna M T Richardson; Alex Gerhard; David Neary; David M A Mann
Journal:  Brain       Date:  2011-08-11       Impact factor: 13.501

6.  Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS.

Authors:  Aidong Yuan; Mala V Rao; Takahiro Sasaki; Yuanxin Chen; Asok Kumar; Ronald K H Liem; Joel Eyer; Alan C Peterson; Jean-Pierre Julien; Ralph A Nixon
Journal:  J Neurosci       Date:  2006-09-27       Impact factor: 6.167

7.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

8.  SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis.

Authors:  G A Rouleau; A W Clark; K Rooke; A Pramatarova; A Krizus; O Suchowersky; J P Julien; D Figlewicz
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

9.  Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions.

Authors:  P H Tu; P Raju; K A Robinson; M E Gurney; J Q Trojanowski; V M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

10.  Neurofilament inclusion body disease: a new proteinopathy?

Authors:  Keith A Josephs; Janice L Holton; Martin N Rossor; Hans Braendgaard; Tetsutaro Ozawa; Nick C Fox; Ronald C Petersen; Gary S Pearl; Milan Ganguly; Pedro Rosa; Henning Laursen; Joseph E Parisi; Gunhild Waldemar; Niall P Quinn; Dennis W Dickson; Tamas Revesz
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501

View more
  6 in total

Review 1.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

2.  Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.

Authors:  Kevin F Bieniek; Keith A Josephs; Wen-Lang Lin; Dennis W Dickson
Journal:  Free Neuropathol       Date:  2020-03-11

Review 3.  Modelling amyotrophic lateral sclerosis in rodents.

Authors:  Tiffany W Todd; Leonard Petrucelli
Journal:  Nat Rev Neurosci       Date:  2022-03-08       Impact factor: 34.870

Review 4.  ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.

Authors:  Illana Gozes; Yanina Ivashko-Pachima
Journal:  Front Aging Neurosci       Date:  2015-10-29       Impact factor: 5.750

5.  Clinicopathological characteristics of patients with amyotrophic lateral sclerosis resulting in a totally locked-in state (communication Stage V).

Authors:  Kentaro Hayashi; Yoko Mochizuki; Ryoko Takeuchi; Toshio Shimizu; Masahiro Nagao; Kazuhiko Watabe; Nobutaka Arai; Kiyomitsu Oyanagi; Osamu Onodera; Masaharu Hayashi; Hitoshi Takahashi; Akiyoshi Kakita; Eiji Isozaki
Journal:  Acta Neuropathol Commun       Date:  2016-09-30       Impact factor: 7.801

6.  MRI Volumetric Analysis of the Thalamus and Hypothalamus in Amyotrophic Lateral Sclerosis.

Authors:  Shan Ye; Yishan Luo; Pingping Jin; Yajun Wang; Nan Zhang; Gan Zhang; Lu Chen; Lin Shi; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.